

Haematologica  
HAEMATOL/2020/274969  
Version 2

New option for improving hematological recovery: suppression of  
luteinizing hormone

Harold K. Elias and Marcel R. M. van den Brink

Disclosures: Dr. Marcel van den Brink has received research support and stock options from Seres; has received stock options from Notch Therapeutics; has received royalties from Wolters Kluwer; has consulted, received honorarium from or participated in advisory boards for Seres Therapeutics, Jazz Pharmaceuticals, Rheos, Therakos, WindMIL Therapeutics, Amgen, Merck & Co, Inc., Magenta Therapeutics, Frazier Healthcare Partners, Nektar Therapeutics, Notch Therapeutics, Forty Seven Inc., Priothera, Ceramedix, DKMS, Pharmacyclics (Spouse), Kite Pharmaceuticals (Spouse); has IP Licensing with Seres Therapeutics and Juno Therapeutics; and holds a fiduciary role on the Foundation Board of DKMS (a nonprofit organization).

Contributions: All authors have contributed equally.